UFFERERS of the asbestos-linked disease mesothelioma will have access to cheap treatment from today, after a long campaign to secure federal government subsidy paid off.
The government says the chemotherapy agent Alimta - the only treatment available specifically for the killer cancer of the lung or stomach lining - will be listed on the Pharmaceutical Benefits Scheme (PBS) from today.
Health Minister Nicola Roxon said the listing of Alimta was an important announcement that followed the "tireless campaigning" of Bernie Banton, who died, aged 61, in November from the disease.
"Bernie was a great Australian hero and it is due to his efforts that many people will understand the significance of this decision," she said.
About 600 Australians are diagnosed annually with mesothelioma, but the long lag time between exposure to asbestos and the onset of symptoms means its prevalence is tipped to rise in the future.
Medical studies have estimated 18,000 people will have become victims of the disease by 2020.
Alimta, which can increase survival time and improve a sufferer's quality of life, has been out of reach for many patients at $20,000 or more for six treatments.
From today, sufferers will pay a maximum of $31.30 for each prescription. Eligible concession-patients will pay $5 for each prescription.
The subsidy will cost the government about $26 million annually and is expected to benefit about 300 people a year.
The listing of the drug became an election issue after Mr Banton criticised then health minister Tony Abbott for failing to personally receive a 17,000-signature petition brought to his Sydney electoral office in October.
Mr Abbott was forced into an embarrassing apology after questioning whether the dying campaigner's motives for speaking out were "pure of heart".
A week later, a government-appointed board recommended the drug be added to the PBS after three times rejecting its listing since 2004.
Mr Abbott bypassed the normal process of cabinet approval by immediately announcing the drug's listing.
Until now, only about half of Australians suffering mesothelioma were getting easy access to the palliative care drug through state government subsidy and workplace compensation schemes.
Thursday, 3 December 2009
Alfacell Deals U.S. Rights for Onconase to Strativa
Alfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million.
Just $5 million will change hands up front, but both Alfacell and Strativa stand to gain much more if their gamble in choosing each other as partners pays off. Specifically, Alfacell could get $30 million for FDA approval of Onconase in unresectable malignant mesothelioma (UMM) and up to $190 million for milestones tied to Onconase sales as well as development and commercialization of the drug in additional indications. Alfacell also would receive double-digit royalties and retains a co-promotion option.
For Alfacell, the gamble lies in choosing Strativa, the recently-launched specialty pharmaceutical division of Par Pharmaceutical Cos. Inc. So far, Strativa markets just one product: Megace ES for anorexia, cachexia and unexplained weight loss in HIV patients. Although the company has deals in place for three additional late-stage products, all three are for HIV or cancer supportive care, and Onconase would be Strativa's first true oncology therapeutic.
Lawrence Kenyon, executive vice president and chief financial officer for Alfacell, told BioWorld Today that Onconase has been the subject of "bids from multiple companies for a number of years." Strativa was selected because it had the hunger of a start-up looking to build an oncology business focused on niche products, combined with the resources and infrastructure of Par Pharmaceuticals, he said.
For Strativa, the gamble lies in Onconase's somewhat checkered development history. The drug, a natural ribonuclease isolated from frog eggs, failed a Phase III trial in pancreatic cancer and its first Phase III trial in UMM.
In the pancreatic cancer trial, a preliminary analysis showed that Onconase plus tamoxifen failed to improve survival compared to 5-fluorouracil. Kenyon said part of the problem was an inability to recruit sufficiently healthy patients into the trial, and the pancreatic cancer program subsequently was discontinued. (See BioWorld Today, July 16, 1998.)
The first Phase III UMM trial compared Onconase as a monotherapy to doxorubicin. Again, there was no survival difference in the overall population, but Kenyon said a retrospective analysis showed that the sickest patients had been disproportionately weighted to the Onconase group. Backing them out of the analysis resulted in a two-month survival difference.
Onconase is now being studied in a Phase IIIb trial designed to confirm the positive data seen in the Phase III subset analysis. The trial, which was designed in coordination with the FDA, compares Onconase plus doxorubicin to doxorubicin alone in the less-severe groups of UMM patients. Enrollment of 428 patients is complete, and Kenyon said the company is "very close" to obtaining the number of clinical events needed to analyze the data.
Under the deal with Strativa, Alfacell will continue to fund development, manufacturing and regulatory work with Onconase, including the ongoing Phase IIIb trial. Strativa will fund U.S. commercialization.
Previous deals with US Pharmacia affiliate USP Pharma Spolka Z.O.O. and Genesis Pharma SA cover Onconase commercialization in Eastern Europe and certain Southeast European countries, respectively.
As of Oct. 31, Alfacell reported $5.4 million in cash and equivalents, most of which was earmarked to support the Onconase trial and new drug application filing. Once the filing is submitted, Alfacell intends to work with Strativa on additional indications for Onconase, including the possibility of moving a non-small-cell lung cancer program into Phase II.
Kenyon said the money from Strativa also will allow Alfacell to "ramp up" its preclinical work on AC 03-636 for glioma and antiviral indications, AC CJ-001 for glioma, and AC CJ-002 for non-Hodgkin's lymphoma.
Shares of Somerset, N.J.-based Alfacell (NASDAQ:ACEL) rose 25 cents, or 14.3 percent, to close at $2 on Tuesday. Meanwhile, shares of Woodcliff Lake, N.J.-based Par Pharmaceuticals (NYSE:PRX) rose 52 cents to close at $21.49.
Just $5 million will change hands up front, but both Alfacell and Strativa stand to gain much more if their gamble in choosing each other as partners pays off. Specifically, Alfacell could get $30 million for FDA approval of Onconase in unresectable malignant mesothelioma (UMM) and up to $190 million for milestones tied to Onconase sales as well as development and commercialization of the drug in additional indications. Alfacell also would receive double-digit royalties and retains a co-promotion option.
For Alfacell, the gamble lies in choosing Strativa, the recently-launched specialty pharmaceutical division of Par Pharmaceutical Cos. Inc. So far, Strativa markets just one product: Megace ES for anorexia, cachexia and unexplained weight loss in HIV patients. Although the company has deals in place for three additional late-stage products, all three are for HIV or cancer supportive care, and Onconase would be Strativa's first true oncology therapeutic.
Lawrence Kenyon, executive vice president and chief financial officer for Alfacell, told BioWorld Today that Onconase has been the subject of "bids from multiple companies for a number of years." Strativa was selected because it had the hunger of a start-up looking to build an oncology business focused on niche products, combined with the resources and infrastructure of Par Pharmaceuticals, he said.
For Strativa, the gamble lies in Onconase's somewhat checkered development history. The drug, a natural ribonuclease isolated from frog eggs, failed a Phase III trial in pancreatic cancer and its first Phase III trial in UMM.
In the pancreatic cancer trial, a preliminary analysis showed that Onconase plus tamoxifen failed to improve survival compared to 5-fluorouracil. Kenyon said part of the problem was an inability to recruit sufficiently healthy patients into the trial, and the pancreatic cancer program subsequently was discontinued. (See BioWorld Today, July 16, 1998.)
The first Phase III UMM trial compared Onconase as a monotherapy to doxorubicin. Again, there was no survival difference in the overall population, but Kenyon said a retrospective analysis showed that the sickest patients had been disproportionately weighted to the Onconase group. Backing them out of the analysis resulted in a two-month survival difference.
Onconase is now being studied in a Phase IIIb trial designed to confirm the positive data seen in the Phase III subset analysis. The trial, which was designed in coordination with the FDA, compares Onconase plus doxorubicin to doxorubicin alone in the less-severe groups of UMM patients. Enrollment of 428 patients is complete, and Kenyon said the company is "very close" to obtaining the number of clinical events needed to analyze the data.
Under the deal with Strativa, Alfacell will continue to fund development, manufacturing and regulatory work with Onconase, including the ongoing Phase IIIb trial. Strativa will fund U.S. commercialization.
Previous deals with US Pharmacia affiliate USP Pharma Spolka Z.O.O. and Genesis Pharma SA cover Onconase commercialization in Eastern Europe and certain Southeast European countries, respectively.
As of Oct. 31, Alfacell reported $5.4 million in cash and equivalents, most of which was earmarked to support the Onconase trial and new drug application filing. Once the filing is submitted, Alfacell intends to work with Strativa on additional indications for Onconase, including the possibility of moving a non-small-cell lung cancer program into Phase II.
Kenyon said the money from Strativa also will allow Alfacell to "ramp up" its preclinical work on AC 03-636 for glioma and antiviral indications, AC CJ-001 for glioma, and AC CJ-002 for non-Hodgkin's lymphoma.
Shares of Somerset, N.J.-based Alfacell (NASDAQ:ACEL) rose 25 cents, or 14.3 percent, to close at $2 on Tuesday. Meanwhile, shares of Woodcliff Lake, N.J.-based Par Pharmaceuticals (NYSE:PRX) rose 52 cents to close at $21.49.
Vermont Mesothelioma Lawyer Shepard helping Mesothelioma Victims in Rhode Island, Boston, New York, New Hampshire
The Mesothelioma Lawyer expresses his concern over the student’s health risks as asbestos that was used in these old school buildings as the primary insulation and fireproofing construction material is now projecting from the school building sites due to poor maintenance. It is contaminating the schools environment posing students, teachers and the staff to mesothelioma cancer and asbestos related respiratory diseases.
The school going students and the staff working in these schools are exposed to the risk of asbestos related respirator diseases thus laying the foundation for mesothelioma. This fact is also reviled by the Mesothelioma and Asbestos Awareness Centers report. The school buildings in New York have now grown old and need maintenance. Due to lack of maintenance in the old building the asbestos which had been used in construction is now exposed. It is polluting the environment endangering the lives of students, teachers and staff exposing them to the risk of contracting asbestos related respiratory diseases and mesothelioma cancer.
During an emergency inspection in NY schools which was carried as a NY City School was blamed for an incident of asbestos exposure. It was reveled during the inspection that 80% of the building built prior to 1980 used asbestos as insulation and fire proof material during the construction phase. Now due to the poor maintenance the risk of exposure of asbestos has increased manifolds posing risk of health to all the occupants of the school buildings. The report by the Mesothelioma and Asbestos Awareness Centers Report also state that in 2004 one Brooklyn School was forced to open late as they had to ensure the safety of the school building, staff and the students.
Even a small amount of asbestos exposure contaminates the environment, increases the possibility of inhalation of asbestos particles thus marking a start of respiratory disorders leading to mesothelioma cancer.
Mesothelioma lawyer Shepard studies all such cases, takes the path of law to bring relief to the injured who had not known about the risks of being exposed to asbestos. At present Shepard Law Firm is assisting Mesothelioma victims in:
* Boston
* New Hampshire
* Vermont
* Rhode Island
However, due to large network Shepard Law firm enjoys, cases from other areas such as Dallas, New York, Houston and other areas where school buildings are getting old and may be of concern resulting in asbestos exposure can contact: The Shepard Law Firm at http://www.shepardlawfirm.com
To learn more about Mesothelioma / Asbestos Risks visit Mesothelioma Cancer Resource
for free informaation
The school going students and the staff working in these schools are exposed to the risk of asbestos related respirator diseases thus laying the foundation for mesothelioma. This fact is also reviled by the Mesothelioma and Asbestos Awareness Centers report. The school buildings in New York have now grown old and need maintenance. Due to lack of maintenance in the old building the asbestos which had been used in construction is now exposed. It is polluting the environment endangering the lives of students, teachers and staff exposing them to the risk of contracting asbestos related respiratory diseases and mesothelioma cancer.
During an emergency inspection in NY schools which was carried as a NY City School was blamed for an incident of asbestos exposure. It was reveled during the inspection that 80% of the building built prior to 1980 used asbestos as insulation and fire proof material during the construction phase. Now due to the poor maintenance the risk of exposure of asbestos has increased manifolds posing risk of health to all the occupants of the school buildings. The report by the Mesothelioma and Asbestos Awareness Centers Report also state that in 2004 one Brooklyn School was forced to open late as they had to ensure the safety of the school building, staff and the students.
Even a small amount of asbestos exposure contaminates the environment, increases the possibility of inhalation of asbestos particles thus marking a start of respiratory disorders leading to mesothelioma cancer.
Mesothelioma lawyer Shepard studies all such cases, takes the path of law to bring relief to the injured who had not known about the risks of being exposed to asbestos. At present Shepard Law Firm is assisting Mesothelioma victims in:
* Boston
* New Hampshire
* Vermont
* Rhode Island
However, due to large network Shepard Law firm enjoys, cases from other areas such as Dallas, New York, Houston and other areas where school buildings are getting old and may be of concern resulting in asbestos exposure can contact: The Shepard Law Firm at http://www.shepardlawfirm.com
To learn more about Mesothelioma / Asbestos Risks visit Mesothelioma Cancer Resource
for free informaation
Signs and Symptoms
Early Signs of Mesothelioma
The early signs and symptoms of mesothelioma are quite similar to pneumonia. They won’t be very apparent until one gets exposed to asbestos ranging from 20-50 years of vigorous contact with it. The early ciphers of mesothelioma are:
* Chest Pain (Right, Left or even in sides)
* Sudden Loss of Weight
* Nausea
* Pain and Swelling in abdomen
* Difficulty in breathing
* Sudden rise in temperature
* Swelling of face, neck or chest.
* Pain in Chest
* Persistent Cough
Since, this cancer is caused due to the Chest cavity and the abdominal cavity, so the above mentioned symptoms are the most common ones in this disease.
Because the chest cavity and abdominal cavity are the primary sites of origin for this form of cancer, most patients who are later diagnosed with mesothelioma have the following signs and symptoms:
Generally, there are two types of Mesothelioma- Pleural and Peritoneal Mesothelioma.
Pleural (Chest) Mesothelioma: Patients suffering from pleural mesothelioma generally experience breathing problems and/or pain in chest or backs. In this form of mesothelioma, thickening of Lung’s membrane takes place which interrupts in the general expansion and contraction of the lungs. The presence of Pleural effusions (the fluid build ups) makes the breathing difficult for the patients.
Peritoneal (Abdominal) Mesothelioma: Patients suffering from peritoneal mesothelioma generally experience pain in abdomens and/or swelling in face/chest or backs. Similar to Pleural Mesothelioma, thickening of the membrane also takes place here, while the fluid gets accumulated in the abdomen.
Anyone with a history of asbestos exposure is strongly recommended to get qualified medical treatment and check up immediately, if they experience any of the symptoms mentioned above. God Bless.
The early signs and symptoms of mesothelioma are quite similar to pneumonia. They won’t be very apparent until one gets exposed to asbestos ranging from 20-50 years of vigorous contact with it. The early ciphers of mesothelioma are:
* Chest Pain (Right, Left or even in sides)
* Sudden Loss of Weight
* Nausea
* Pain and Swelling in abdomen
* Difficulty in breathing
* Sudden rise in temperature
* Swelling of face, neck or chest.
* Pain in Chest
* Persistent Cough
Since, this cancer is caused due to the Chest cavity and the abdominal cavity, so the above mentioned symptoms are the most common ones in this disease.
Because the chest cavity and abdominal cavity are the primary sites of origin for this form of cancer, most patients who are later diagnosed with mesothelioma have the following signs and symptoms:
Generally, there are two types of Mesothelioma- Pleural and Peritoneal Mesothelioma.
Pleural (Chest) Mesothelioma: Patients suffering from pleural mesothelioma generally experience breathing problems and/or pain in chest or backs. In this form of mesothelioma, thickening of Lung’s membrane takes place which interrupts in the general expansion and contraction of the lungs. The presence of Pleural effusions (the fluid build ups) makes the breathing difficult for the patients.
Peritoneal (Abdominal) Mesothelioma: Patients suffering from peritoneal mesothelioma generally experience pain in abdomens and/or swelling in face/chest or backs. Similar to Pleural Mesothelioma, thickening of the membrane also takes place here, while the fluid gets accumulated in the abdomen.
Anyone with a history of asbestos exposure is strongly recommended to get qualified medical treatment and check up immediately, if they experience any of the symptoms mentioned above. God Bless.
Razed home's owner takes step to sue city
$1M NOTICE OF CLAIM: Columbia Street residence, called 'the cat house,' was torn down after fire Nov. 12
The man who owns a home on Columbia Street that was referred to as "the cat house" by neighbors has filed a notice of claim for $1 million against the city of Watertown for razing its remains after a fire last year.
A notice of claim is a precursor to filing a lawsuit against a municipality.
Oliver J. Wisner is seeking compensation for the "arbitrary, capricious and malicious charging and billing for outrageous unnecessary work on the cleanup of ashes and debris" the claim states.
The Watertown lawyer owns the property at 1205-07 Columbia St., which burned down Nov. 12, forcing neighbors to evacuate their homes during the early morning hours. The heat from the blaze damaged nearby homes, one of which is still uninhabitable.
The city requested that Mr. Wisner remove the remaining debris from the duplex immediately following the blaze. In late December, the city hired Independent Commercial Contractors Inc., Lorraine, for $28,600 to clean the site and remove asbestos. Mr. Wisner was then billed for the job.
Mr. Wisner bought the home June 21, despite the previous owner not allowing him to completely inspect it beforehand, the notice states.
Once the purchase was complete, Mr. Wisner hired cleaners to clear debris from the home.
"The cleaners discovered more than 10 bodies of long-dead cats in the building," the notice states. "The odor from the house and the Dumpsters brought numerous complaints from neighbors."
In June, the city Code Enforcement Office found that an upstairs bathtub in 1205 Columbia St. was filled with cat feces, and cat skeletons were found throughout the apartment.The property was condemned and the tenant, Michael J. Sias, was removed.
Mr. Sias, 58, now of 536 Emerson St., Apt. 103, is facing an animal-cruelty charge on allegations that between June 25 and July 3 he deprived seven cats of necessary sustenance in his former home, "permitting unjustifiable physical pain, suffering and death," according to a city police document. He was charged Tuesday and faces prosecution in City Court.
Some live cats were taken from the home by the SPCA, others were euthanized and six frozen bodies that were found in an operating freezer were sent to Cornell University, Ithaca, for a forensics examination.
Mr. Wisner claims that "it was a matter of public knowledge that persons in the city of Watertown, New York, had called for the burning of the duplex." Throughout the notice, he maintains that an arsonist started the fire and that police did not properly follow leads.
The cause of the fire was never determined and police never made an arrest.
"My position is that there was no emergency and the demolition charges were unlawful and unreasonable and should be reviewed by a court and disallowed as an unlawful taking of private property," the notice states.
Mr. Wisner is asking for $100,000 for the loss of the house and $900,000 for "harassment causing great mental stress and depression." He plans to retain an attorney, the notice states.
City Attorney Robert J. Slye said he did not want to comment about the notice when contacted Friday afternoon.
"We'll certainly wait to see what Mr. Wisner has to say and if he files a suit," he said.
Times staff writer David C. Shampine contributed to this report.
Source
The man who owns a home on Columbia Street that was referred to as "the cat house" by neighbors has filed a notice of claim for $1 million against the city of Watertown for razing its remains after a fire last year.
A notice of claim is a precursor to filing a lawsuit against a municipality.
Oliver J. Wisner is seeking compensation for the "arbitrary, capricious and malicious charging and billing for outrageous unnecessary work on the cleanup of ashes and debris" the claim states.
The Watertown lawyer owns the property at 1205-07 Columbia St., which burned down Nov. 12, forcing neighbors to evacuate their homes during the early morning hours. The heat from the blaze damaged nearby homes, one of which is still uninhabitable.
The city requested that Mr. Wisner remove the remaining debris from the duplex immediately following the blaze. In late December, the city hired Independent Commercial Contractors Inc., Lorraine, for $28,600 to clean the site and remove asbestos. Mr. Wisner was then billed for the job.
Mr. Wisner bought the home June 21, despite the previous owner not allowing him to completely inspect it beforehand, the notice states.
Once the purchase was complete, Mr. Wisner hired cleaners to clear debris from the home.
"The cleaners discovered more than 10 bodies of long-dead cats in the building," the notice states. "The odor from the house and the Dumpsters brought numerous complaints from neighbors."
In June, the city Code Enforcement Office found that an upstairs bathtub in 1205 Columbia St. was filled with cat feces, and cat skeletons were found throughout the apartment.The property was condemned and the tenant, Michael J. Sias, was removed.
Mr. Sias, 58, now of 536 Emerson St., Apt. 103, is facing an animal-cruelty charge on allegations that between June 25 and July 3 he deprived seven cats of necessary sustenance in his former home, "permitting unjustifiable physical pain, suffering and death," according to a city police document. He was charged Tuesday and faces prosecution in City Court.
Some live cats were taken from the home by the SPCA, others were euthanized and six frozen bodies that were found in an operating freezer were sent to Cornell University, Ithaca, for a forensics examination.
Mr. Wisner claims that "it was a matter of public knowledge that persons in the city of Watertown, New York, had called for the burning of the duplex." Throughout the notice, he maintains that an arsonist started the fire and that police did not properly follow leads.
The cause of the fire was never determined and police never made an arrest.
"My position is that there was no emergency and the demolition charges were unlawful and unreasonable and should be reviewed by a court and disallowed as an unlawful taking of private property," the notice states.
Mr. Wisner is asking for $100,000 for the loss of the house and $900,000 for "harassment causing great mental stress and depression." He plans to retain an attorney, the notice states.
City Attorney Robert J. Slye said he did not want to comment about the notice when contacted Friday afternoon.
"We'll certainly wait to see what Mr. Wisner has to say and if he files a suit," he said.
Times staff writer David C. Shampine contributed to this report.
Source
October has been designated Healthy Lung Month
The smell of burning leaves, an apple pie baking in the oven, or a wood fire in a neighbor's fireplace often evoke memories of special people and experiences from past autumns. While we may be mindful of inhaling deeply to enjoy these scents, we seldom give thought to what happens to the air we breathe in.
We all know we need the oxygen in the air to live, but unless we experience breathing difficulties, most of us rarely think about our lungs at all.
The lungs are complex organs, considered far more complicated than the heart. They not only take the oxygen from the air and send it into the bloodstream for delivery throughout the body, but the lungs filter out substances like dust, pollen, viruses, and bacteria from the air we breathe. They are also responsible for eliminating waste from the bloodstream. It is clear lung health is important, and October has been designated Healthy Lung Month in recognition of this fact.
If all types of lung disease are combined, it is the 3rd highest cause of death in the United States. Over 35 million Americans live with an ongoing lung disease like asthma or chronic obstructive pulmonary disease (COPD). Lung disease is the cause of 1 in 7 deaths annually in this country.
Unfortunately, it can be easy to overlook early signs of lung disease. At first, many people simply realize they do not have much energy. But as the lung condition worsens, other symptoms become more apparent. Trouble breathing, shortness of breath, reduced ability to exercise, feeling like you are not getting enough air, a chronic cough, coughing up blood or mucus, or pain when inhaling and exhaling, are among the signs of lung disease.
Common lung conditions include:
* Asthma, which affects 20 million Americans. It causes inflammation and swelling of the airways in the lungs. The narrow airways limits the flow of air in and out of the lungs, causing wheezing, coughing, tightness in the chest, and difficulty breathing
.
* COPD, which includes emphysema and chronic obstructive bronchitis. Both conditions cause inflammation of the bronchial tubes that carry air to the lungs. This leads to thickening and scarring of the lining of the bronchial tubes and the production of excess mucus, making breathing difficult. COPD is the 4th leading cause of death in the United States.
* Lung cancer, now the leading cause of cancer deaths in American women, is characterized by the abnormal, uncontrolled growth of malignant lung cells.
These cells invade and destroy normal cells in nearby tissues and can spread to other parts of the body.
Fortunately, the risk of developing lung disease can be reduced. First, if you are a smoker, quit. Whether a smoker or a non-smoker, everyone should try to avoid second-hand smoke.
Second, eating a healthy diet, rich in fruits and vegetables, lowers the risk of cancer. Drinking plenty of water helps to replace moisture lost when we exhale, keeping the lung tissue moist and healthy.
Exercise is also important for healthy lungs, stimulating the blood flow required for the lungs to function optimally.
Lung health also benefits from getting vaccinated against the flu every year. Influenza (and pneumonia, often a complication of the flu), damages lung tissue and leads to a number of adverse health effects.
In addition to the above, avoiding environmental hazards such as asbestos and radon is also important in protecting lung health. Protective clothing and a face mask are required for anyone working in a job that entails exposure to asbestos. Radon in the home can be measured with a test kit to determine if remediation is advised.
The Central Connecticut Health District, serving the towns of Berlin, Newington, Rocky Hill, and Wethersfield, sponsors a number of flu shot clinics where pneumonia shots are also available. The Health District also sells low-cost radon test kits. For further information about flu clinics, radon kits, and other public health concerns, contact the Health District at 860-721-2822 (www.ccthd.org). Specific information about lung health and lung disease is available through the American Lung Association at 1-800-548-8252 (www.lungusa.org) and the National Women's Health Information Center at 1-800-994-9662 or 1-888-220-5446 for the hearing impaired (www.4women.gov).
We all know we need the oxygen in the air to live, but unless we experience breathing difficulties, most of us rarely think about our lungs at all.
The lungs are complex organs, considered far more complicated than the heart. They not only take the oxygen from the air and send it into the bloodstream for delivery throughout the body, but the lungs filter out substances like dust, pollen, viruses, and bacteria from the air we breathe. They are also responsible for eliminating waste from the bloodstream. It is clear lung health is important, and October has been designated Healthy Lung Month in recognition of this fact.
If all types of lung disease are combined, it is the 3rd highest cause of death in the United States. Over 35 million Americans live with an ongoing lung disease like asthma or chronic obstructive pulmonary disease (COPD). Lung disease is the cause of 1 in 7 deaths annually in this country.
Unfortunately, it can be easy to overlook early signs of lung disease. At first, many people simply realize they do not have much energy. But as the lung condition worsens, other symptoms become more apparent. Trouble breathing, shortness of breath, reduced ability to exercise, feeling like you are not getting enough air, a chronic cough, coughing up blood or mucus, or pain when inhaling and exhaling, are among the signs of lung disease.
Common lung conditions include:
* Asthma, which affects 20 million Americans. It causes inflammation and swelling of the airways in the lungs. The narrow airways limits the flow of air in and out of the lungs, causing wheezing, coughing, tightness in the chest, and difficulty breathing
.
* COPD, which includes emphysema and chronic obstructive bronchitis. Both conditions cause inflammation of the bronchial tubes that carry air to the lungs. This leads to thickening and scarring of the lining of the bronchial tubes and the production of excess mucus, making breathing difficult. COPD is the 4th leading cause of death in the United States.
* Lung cancer, now the leading cause of cancer deaths in American women, is characterized by the abnormal, uncontrolled growth of malignant lung cells.
These cells invade and destroy normal cells in nearby tissues and can spread to other parts of the body.
Fortunately, the risk of developing lung disease can be reduced. First, if you are a smoker, quit. Whether a smoker or a non-smoker, everyone should try to avoid second-hand smoke.
Second, eating a healthy diet, rich in fruits and vegetables, lowers the risk of cancer. Drinking plenty of water helps to replace moisture lost when we exhale, keeping the lung tissue moist and healthy.
Exercise is also important for healthy lungs, stimulating the blood flow required for the lungs to function optimally.
Lung health also benefits from getting vaccinated against the flu every year. Influenza (and pneumonia, often a complication of the flu), damages lung tissue and leads to a number of adverse health effects.
In addition to the above, avoiding environmental hazards such as asbestos and radon is also important in protecting lung health. Protective clothing and a face mask are required for anyone working in a job that entails exposure to asbestos. Radon in the home can be measured with a test kit to determine if remediation is advised.
The Central Connecticut Health District, serving the towns of Berlin, Newington, Rocky Hill, and Wethersfield, sponsors a number of flu shot clinics where pneumonia shots are also available. The Health District also sells low-cost radon test kits. For further information about flu clinics, radon kits, and other public health concerns, contact the Health District at 860-721-2822 (www.ccthd.org). Specific information about lung health and lung disease is available through the American Lung Association at 1-800-548-8252 (www.lungusa.org) and the National Women's Health Information Center at 1-800-994-9662 or 1-888-220-5446 for the hearing impaired (www.4women.gov).
Mesothelioma and Early Lung Cancer Identified by Screening
sing computed tomography scans to screen former asbestos workers can detect both early and late-stage lung cancer and late-stage mesothelioma, according to a study in the May Journal of Thoracic Oncology. However, it’s still not clear whether screening for these cancers might improve patients’ prognoses.
Exposure to asbestos fibers is a known risk factor for lung cancer and the cause of mesothelioma. Although asbestos is still not completely banned in the U.S., it was phased out of American industry to a large degree beginning in the 1970s. However because asbestos-related diseases can take 20 to 40 years to emerge after people have been exposed, former asbestos workers and those exposed to products containing this carcinogen continue to be diagnosed with asbestos caused cancers.
As researchers search for better treatments and even a cure for these diseases, they are also focusing on new diagnostic methods that might identify the cancers earlier. Early diagnosis is particularly crucial with mesothelioma, because many patients survive only one year after they first start to show signs, and symptoms are often difficult to distinguish from those of other lung diseases.
One potential screening method uses low-dose computed tomography (LDCT) to evaluate the lungs and their lining (pleura). LDCT can locate plaques in the lungs, which are a sign of asbestos exposure and have been linked to an increased cancer risk.
Currently, there are no recommendations about using LDCT or any other method to screen people who have been exposed to asbestos, and screening isn’t routinely done. “There are currently no methods for the early detection of mesothelioma available,” says lead author Heidi Roberts, MD, Associate Professor of Radiology at the University of Toronto. “This is why we are doing the research.”
To determine the effectiveness of LDCT as a screening tool for asbestos-related lung cancers, Dr. Roberts and her colleagues recruited 516 people (most of them men) who had been exposed to asbestos at least 20 years before, or who had known plaques. Participants were given LDCT scans of the chest. Patients who had abnormal scans were given follow-up tests. Those with normal test results were invited to have an annual LDCT scan.
Of the 516 participants, 357 had evidence of plaques. Based on the results of the first scan and annual scans, six of the patients were diagnosed with lung cancers and four were diagnosed with mesothelioma.
Although LDCT was able to detect advanced mesothelioma, as well as early- and late-stage lung cancers, it was not able to diagnose early mesothelioma. The study authors say they need to continue screening patients to help them get a better idea of what early mesothelioma looks like. Also, they say adding biomarkers (substances in the blood that indicate the presence of cancer) to the screening process may provide greater sensitivity to help diagnose those at very high risk for mesothelioma.
Even as techniques are fine-tuned, screening is just one step of a three-tiered effort to combat these cancers, according to Dr. Roberts. “The second step is the parallel development of biomarkers, and the third step is the parallel development of treatment strategies,” she says. “These have to be developed hand-in-hand in order to make this a useful and meaningful tool.”
Exposure to asbestos fibers is a known risk factor for lung cancer and the cause of mesothelioma. Although asbestos is still not completely banned in the U.S., it was phased out of American industry to a large degree beginning in the 1970s. However because asbestos-related diseases can take 20 to 40 years to emerge after people have been exposed, former asbestos workers and those exposed to products containing this carcinogen continue to be diagnosed with asbestos caused cancers.
As researchers search for better treatments and even a cure for these diseases, they are also focusing on new diagnostic methods that might identify the cancers earlier. Early diagnosis is particularly crucial with mesothelioma, because many patients survive only one year after they first start to show signs, and symptoms are often difficult to distinguish from those of other lung diseases.
One potential screening method uses low-dose computed tomography (LDCT) to evaluate the lungs and their lining (pleura). LDCT can locate plaques in the lungs, which are a sign of asbestos exposure and have been linked to an increased cancer risk.
Currently, there are no recommendations about using LDCT or any other method to screen people who have been exposed to asbestos, and screening isn’t routinely done. “There are currently no methods for the early detection of mesothelioma available,” says lead author Heidi Roberts, MD, Associate Professor of Radiology at the University of Toronto. “This is why we are doing the research.”
To determine the effectiveness of LDCT as a screening tool for asbestos-related lung cancers, Dr. Roberts and her colleagues recruited 516 people (most of them men) who had been exposed to asbestos at least 20 years before, or who had known plaques. Participants were given LDCT scans of the chest. Patients who had abnormal scans were given follow-up tests. Those with normal test results were invited to have an annual LDCT scan.
Of the 516 participants, 357 had evidence of plaques. Based on the results of the first scan and annual scans, six of the patients were diagnosed with lung cancers and four were diagnosed with mesothelioma.
Although LDCT was able to detect advanced mesothelioma, as well as early- and late-stage lung cancers, it was not able to diagnose early mesothelioma. The study authors say they need to continue screening patients to help them get a better idea of what early mesothelioma looks like. Also, they say adding biomarkers (substances in the blood that indicate the presence of cancer) to the screening process may provide greater sensitivity to help diagnose those at very high risk for mesothelioma.
Even as techniques are fine-tuned, screening is just one step of a three-tiered effort to combat these cancers, according to Dr. Roberts. “The second step is the parallel development of biomarkers, and the third step is the parallel development of treatment strategies,” she says. “These have to be developed hand-in-hand in order to make this a useful and meaningful tool.”
Subscribe to:
Posts (Atom)